UNSPSC 51384530: Ketoprofen sodium

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H13O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5R10M39KS7, chemically known as benzeneacetic acid, 3-benzoyl-alpha-methyl-, sodium salt but more generally known as ketoprofen sodium, which bears US NIH Compound Identifier 42390. European Medicines Agency schedules Ketoprofen sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB26651.

Most nations, for tariff and trade purposes, schedule ketoprofen sodium under HS 29183000 and SITC 51395. As of Q4 2014, KETOPROFEN SODIUM remains US FDA's Preferred Term for this commodity. SMILES: CC(C1CCCC(C1)C(=O)C2CCCCC2)C(=O)[O-].[NA+].

UNSPSC 51384530 Ketoprofen sodium is a Commodity-level code that nominally covers a single active pharmaceutical ingredient, but recent state and local opportunities show the code capturing broader pharmaceutical and medical supply procurement that diverges from the narrow scope suggested by the code name. State and local buyers soliciting under this code are pursuing generic multi-source pharmaceuticals, over-the-counter products, naloxone kits, and drug deactivation systems — acquisitions that address public health, emergency response, and pharmacy benefit management rather than ketoprofen sodium specifically. Issuing bodies include state health and human services commissions, county governments, and cooperative purchasing alliances. The Texas Health and Human Services Commission and Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) are active buyers in the space, with MMCAP administering multi-state pharmaceutical contracts. Seminole County, Florida is a representative local issuer pursuing annual procurement of naloxone and drug deactivation systems.

Recent activity spans three states. Texas issued RFI HHS0017013 in April 2026 to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, signaling a strategic shift toward cost containment in state employee and self-insured health plans. Minnesota's MMCAP released RFP S1070000015802 on January 20, 2026, with a due date of March 26, 2026, to establish multiple-award contracts for generic pharmaceuticals and OTC products distributed through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson, with pricing weighted at 75 percent of the evaluation and contract awards effective July 1, 2026. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems on a fixed-fee basis with quarterly deliveries and a two-year initial term plus one-year renewal option. Vendors in the MMCAP procurement must hold commercial general liability insurance of $5,000,000 per occurrence and comply with current Good Manufacturing Practices and the Drug Supply Chain Security Act.